A silver lining for Endocyte

May 2, 2014
Back to TopCommentsE-mailPrintBookmark and Share

The news this morning couldn’t have been worse for Endocyte Inc.

But if it had to come, the timing couldn’t have been better.

The West Lafayette-based drug development firm halted a large clinical trial of its leading cancer drug, vintafolide, for women with ovarian cancer. That sent its stock plunging more than 60 percent.

But the bad news on vintafolide didn’t come until AFTER the drug was given the green light for a market launch by the key regulatory panel in Europe on March 21.

And not until AFTER vintafolide showed promise as a lung cancer drug, also in late-March.

And not until AFTER Endocyte used the investor euphoria that followed those two positive announcements to raise an additional $101.8 million in an April stock offering.

So while CEO Ron Ellis, CFO Mike Sherman and the rest of the team at Endocyte must have felt sick to their stomachs when they read an independent statistical analysis that said vintafolide wasn’t working in ovarian cancer patients, they can at least feel good that the latest stock leaves them a $233 million pile of cash they can use to develop other drugs.

Since the company had a burn rate last year of $83 million (part of which was funded by Merck & Co. Inc., which has purchased the rights to vintafolide), that money should last a while.

Of course, they need it to, because bringing drugs to market is not a quick business. Endocyte was founded by Purdue University chemist Phillip Low in 1995—and it still has no drugs on the market.

And as Endocyte’s see-saw fortunes in just the past six weeks prove, drug development is a brutally risky business.

"Given the set-up, we see this as an overwhelmingly worst-case scenario," wrote Baird Equity Research analyst Christopher Raymond, in a note to investors Friday morning. He added, "We see a long road back to credibility."

Endocyte and Merck are still reviewing the data on vintafolide as an ovarian cancer treatment, so there’s an outside chance the drug might be resurrected in that therapeutic area. But it’s doubtful. The recommendation to halt the Phase 3 clinical trial came from the Data Safety Monitoring Board based on its analysis of progression-free survival in patients. If vintafolide isn’t helping cancer patients live cancer-free longer, then there’s little hope for it.

But vintafolide could still turn out to be effective as a lung cancer drug. And Merck would fund the development of vintafolide on that, too.

The truly worst-case scenario for Endocyte would be for Merck to pull out entirely. That would leave Endocyte with only drugs that are in Phase 1 clinical trials, and probably years to go before reaching the market.

But whatever happens, Endocyte will now spend its cash hoard on its other drugs in development. Those include EC1169, which could treat prostate cancer patients, and EC1456, which some have billed as a better version of vintafolide.

“We are in a strong financial position to continue to advance our promising clinical programs,” Ellis said in a press release this morning.

ADVERTISEMENT

Post a comment to this blog

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT
  1. I think the poster was being sarcastic and only posting or making fun of what is usually posted on here about anything being built in BR or d'town for that matter.

  2. Great news IRL fans: TURBO the IMS sanctioned movie about slugs running the Indy 500 has caught the Securities and Exchange Commission because Dreamworks had to take a $132MILLION write down...because the movie was such a flop. See, the Indy/IMS magic soiled another pair of drawers. Bwahahahahahaha! How's CARTOWN doing? HAHAHAHA...Indy is for losers.

  3. So disappointed in WIBC. This is the last straw to lose a good local morning program. I used to be able to rely on WIBC to give me good local information, news, weather and traffic on my 45 minute commute.Two incidents when I needed local, accurate information regarding severe weather were the first signs I could not now rely on WIBC. I work weekend 12 hour nights for a downtown hospital. This past winter when we had the worst snowfall in my 50 years of life, I came home on a Sunday morning, went to sleep (because I was to go back in Sunday night for another 12 hour shift), and woke up around 1 p.m. to a house with no electricity. I keep an old battery powered radio around and turned on WIBC to see what was going on with the winter storm and the roads and the power outage. Sigh. Only policital stuff. Not even a break in to update on the winter storm warning. The second weather incident occurred when I was driving home during a severe thunderstorm a few months ago. I had already gotten a call from my husband that a tornado warning was just southwest of where I had been. I turned to WIBC to find out what direction the storm was headed so I could figure out a route home, only to find Rush on the air, and again, no breaking away from this stupidity to give me information. Thank God for my phone, which gave me the warning that I was driving in an area where a tornado was seen. Thanks for nothing WIBC. Good luck to you, Steve! We need more of you and not the politics of hatred that WIBC wants to shove at us. Good thing I have Satellite radio.

  4. I read the retail roundup article and tried Burritos and Beers tonight. I'm glad I did, for the food was great. Fresh authentic Mexican food. Great seasoning on the carne asada. A must try!!! Thanks for sharing.

  5. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...

ADVERTISEMENT